Incanthera has been awarded £375,000 from the North West Fund for Biomedical for investment in new cancer treatments. The University of Bradford spin-out company has relocated to Liverpool and will use the funding to complete several pre-trial clinical studies and begin clinical trials by the end of 2012. The North West Fund for Biomedical is administrated by Spark Impact, and is a sub-fund of the £185m evergreen North West Fund. Dr Penny Attridge, senior investment director at Spark Impact and manager of the North West Fund for Biomedical, said: "I am delighted to announce this investment into Incanthera. It's a great privilege to be able to provide funds for such a high quality product developed by a world-class team in an area as important as cancer therapeutics." To date the fund, which is financed by the European Regional Development Fund and the European Investment Bank, has received more than 200 applications. There have been 13 deals over the past year and the funding received by Incanthera is the scheme's third largest investment.
Original Article: Incanthera clinches £375k cancer treatment funds